Gold: Path depends on yield regime shift – MUFG
MUFG’s Derek Halpenny and Abdul-Ahad Lockhart highlight that Gold’s recent strength alongside USD weakness and higher US yields has not historically confirmed a debasement story. They find that in past episodes, Gold often corrected as DXY stabilised, but if US yields were to fall materially, history points to a regime where Gold rallies further and sustained Dollar softness becomes more likely.
Yield dynamics key for Gold outlook
Our analysis examines similar previous episodes of USD weakness, gold strength and rising Treasury yields testing whether subsequent market behaviour validates the debasement narrative. The historical evidence suggests it does not.
"Across prior episodes, extreme readings in the signal were not followed by persistent USD weakness. Instead, DXY typically stabilised, while gold frequently corrected over the subsequent one to three months."
"If that backdrop were to change and yields began falling materially, history points to a different regime."
"In previous episodes where USD weakness and gold strength coincided with declining yields, gold continued to rally and sustained USD softness became more likely."
"A move from rising to falling yields represents an important signal that the market is transitioning from a fiscal and term-premium story towards an easing-driven USD bearish environment."
"As long as yields remain elevated, the more likely outcome is dollar stabilisation, gold consolidation and selective outperformance in carry-sensitive FX rather than a sustained debasement."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The second wave of energy price increases is looming! European Central Bank’s Lane warns: eurozone inflation will be higher and more persistent
Philip Lane, Chief Economist of the European Central Bank, stated that a new round of high energy prices means inflation in the eurozone will remain elevated for longer than the ECB initially anticipated.
Bitcoin Trades Around $86K as FOMO Hits Highest Level Since 2024

siRNA rising star ADARx (ADRX.US) launches $350 millions IPO, AbbVie subscribes to 4.9% of shares with a maximum investment of $100 millions
ADARx plans to raise $350 millions and list on Nasdaq. AbbVie will invest up to $100 millions to acquire a 4.9% stake, with a median valuation of $1.8 billions.
Roche (RHHBY.US) weight loss injection shows positive mid-term trial results: average weight loss of 15.5% over 48 weeks, blood sugar levels drop by 2.65%.
The experimental weight-loss injection enicepatide simultaneously lowered blood sugar and body weight in overweight or obese patients with type 2 diabetes during a mid-stage clinical trial.
